Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.


September 13, 2024
PresentationTivozanib

ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study

March 9, 2024
PublicationTivozanib

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial | The Oncologist | Oxford Academic

Authors: Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, Bernard Escudier, Thomas E. Hutson, Vijay Kasturi, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Elena Verzoni. Click here for link to article.

November 1, 2023
PresentationFiclatuzumab

SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

September 28, 2023
PresentationAV-380

CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels

July 6, 2023
PublicationTivozanib

Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study

Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott. Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.

June 14, 2023
PublicationTivozanib

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

Authors: Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal. Click here for link to article.